Category: Q3Syndicate content

Globus, up on Q3 beat, surprises with CFO resignation

October 31, 2014 by Brad Perriello

Globus Medical shares gain on its better-than-forecast 3rd quarter as the orthopedics company announces the surprise resignation of CFO Richard Baron.

Globus, up on Q3 beat, surprises with CFO resignation

Temporary tax hit pushes NuVasive into Q3 red

October 31, 2014 by Brad Perriello

NuVasive swings to a 3rd-quarter loss on higher-than-expected taxes, but beats Wall Street's sales expectations and says it expects to recoup the loss next quarter.

Temporary tax hit pushes NuVasive into Q3 red

U.S. sales narrow HeartWare's Q3 losses

October 31, 2014 by Val Kennedy

HeartWare posts narrowed 3rd-quarter losses thanks to increased sales of its implantable heart pumps in the U.S.

U.S. sales narrow HeartWare's Q3 losses

HeartWare International (NSDQ:HTWR) yesterday reported narrowed 3rd-quarter losses and significantly higher revenues, boosted by a 39% jump in U.S. sales of its implantable heart pumps.

Pelvic mesh lawsuits push Coloplast's annual profits down

October 30, 2014 by Brad Perriello

Coloplast posts its 1st profits decline in 7 years on mounting legal costs stemming from U.S. product liability lawsuits filed over its pelvic mesh products.

Pelvic mesh lawsuits push Coloplast's annual profits down

Smith & Nephew gains on Q3 results

October 30, 2014 by Brad Perriello

Shares of Smith & Nephew are up today on solid 3rd-quarter results, including 6% growth for its U.S. hip implant business.

Smith & Nephew gains on Q3 results

Abiomed jumps on FDA deal for Impella indication

October 30, 2014 by Brad Perriello

Abiomed says it's come to an agreement with the FDA on an indication for its flagship Impella 2.5 heart pump, and now expects to win pre-market approval early next year without a hearing before an FDA advisory panel.

Abiomed jumps on deal with FDA

Alere to sell Alere Health unit to Optum for $600m

October 28, 2014 by Val Kennedy

Alere says it plans to sell its health-management unit to Optum for $600 million in cash in order to focus on its core rapid diagnostics business.

Alere to sell Alere Health unit to Optum for $600m

Alere agreed to sell Alere Health, its health-management unit, to health-services provider Optum for $600 million in cash in order to focus on its core rapid diagnostics business.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp